NO20061085L - Kombinasjonsterapi for glykemisk kontroll - Google Patents

Kombinasjonsterapi for glykemisk kontroll

Info

Publication number
NO20061085L
NO20061085L NO20061085A NO20061085A NO20061085L NO 20061085 L NO20061085 L NO 20061085L NO 20061085 A NO20061085 A NO 20061085A NO 20061085 A NO20061085 A NO 20061085A NO 20061085 L NO20061085 L NO 20061085L
Authority
NO
Norway
Prior art keywords
combination therapy
glycemic control
diabetes mellitus
diabetes
niddm
Prior art date
Application number
NO20061085A
Other languages
English (en)
Norwegian (no)
Inventor
Hans-Ulrich Demuth
Matthias Hoffmarm
Konrad Glund
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of NO20061085L publication Critical patent/NO20061085L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
NO20061085A 2003-09-02 2006-03-06 Kombinasjonsterapi for glykemisk kontroll NO20061085L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49953503P 2003-09-02 2003-09-02
PCT/IB2004/003082 WO2005020983A2 (en) 2003-09-02 2004-09-02 Combination therapy for glycaemic control

Publications (1)

Publication Number Publication Date
NO20061085L true NO20061085L (no) 2006-05-31

Family

ID=34272835

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061085A NO20061085L (no) 2003-09-02 2006-03-06 Kombinasjonsterapi for glykemisk kontroll

Country Status (14)

Country Link
US (1) US20060287251A1 (OSRAM)
EP (1) EP1663200A2 (OSRAM)
JP (1) JP2007504213A (OSRAM)
KR (1) KR20060119927A (OSRAM)
CN (1) CN1845731A (OSRAM)
AU (1) AU2004267955A1 (OSRAM)
BR (1) BRPI0413204A (OSRAM)
CA (1) CA2536432A1 (OSRAM)
EA (1) EA200600356A1 (OSRAM)
IL (1) IL173844A0 (OSRAM)
MX (1) MXPA06002127A (OSRAM)
NO (1) NO20061085L (OSRAM)
WO (1) WO2005020983A2 (OSRAM)
ZA (1) ZA200601770B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0526291D0 (en) * 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
FR2896157B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
GB0623892D0 (en) * 2006-11-29 2007-01-10 Medical Res Council Technology Assay
JP2013523620A (ja) * 2010-03-26 2013-06-17 ノヴォ ノルディスク アー／エス 新規のグルカゴンアナログ
SG11201401175SA (en) * 2011-10-28 2014-09-26 Sanofi Aventis Deutschland Treatment protocol of diabetes type 2

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19823831A1 (de) * 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE29924609U1 (de) * 1999-05-28 2004-04-22 Probiodrug Ag Neue Effektoren von Dipeptidylpeptidase IV
DE122008000018I1 (de) * 2000-01-21 2008-08-14 Novartis Pharma Ag Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica
US6890905B2 (en) * 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
IL163629A0 (en) * 2002-02-28 2005-12-18 Prosidion Ltd Glutaminyl derivatives and pharmaceutical compositions containing the same
AU2003293311A1 (en) * 2002-09-18 2004-04-23 Prosidion Ltd. Secondary binding site of dipeptidyl peptidase iv (dp iv)

Also Published As

Publication number Publication date
WO2005020983A3 (en) 2005-07-28
IL173844A0 (en) 2006-07-05
KR20060119927A (ko) 2006-11-24
CN1845731A (zh) 2006-10-11
ZA200601770B (en) 2007-07-25
CA2536432A1 (en) 2005-03-10
WO2005020983A2 (en) 2005-03-10
JP2007504213A (ja) 2007-03-01
US20060287251A1 (en) 2006-12-21
MXPA06002127A (es) 2006-05-31
EP1663200A2 (en) 2006-06-07
EA200600356A1 (ru) 2006-08-25
BRPI0413204A (pt) 2006-10-03
AU2004267955A1 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
MXPA05007485A (es) Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
NO20082790L (no) Behandling av type 2 diabetes med en kombinasjon av DPIV inhibitor og metformin eller thiazolidindion
MY161472A (en) Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
YU58603A (sh) Kombinacija aktivatora receptora aktiviranih peroksizom proliferatora (ppar) i inhibitora apsorpcije sterola i lečenje vaskularnih indikacija
NO20070510L (no) Fremgangsmater og reagenser for behandling av metabole forstyrrelser
MXPA03006631A (es) Combinaciones de secuestrante(s) de los acidos biliares y de inhibidor(es) de la absorcion de los esteroles, y tratamiento para indicaciones vasculares.
MXPA05002930A (es) Composiciones para la inhibicion de la proteina cinasa c alfa para el tratamiento de diabetes mellitus y enfermedades cardiovasculares.
MX2009005935A (es) Compuestos biciclicos y su uso como anti-diabeticos.
NO20080217L (no) B-celle reduksjon ved anvendelse av CD20-spesifikke bindingsmolekyler
MX2010001560A (es) Composicion farmaceutica que comprende un inhibidor de sglt2 en combinacion con un inhibidor de dpp-iv.
UA102429C2 (ru) Фармацевтическая композиция, которая включает ингибитор sglt-2, ингибитор дпп-iv и другой антидиабетический агент, и ее применение
MY143599A (en) Pyrazole derivatives, compositions containing such compounds and methods of use
NO20071144L (no) Middel for a tilveiebringe substrater basert pa cellulose og/eller stivelse med vannfrastotende og samtidig soppdrepende, antibakterielle, insektfrastotende og algemotvirkende egenskaper
PL352756A1 (en) A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
PL1694354T3 (pl) Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny
ATE271880T1 (de) Methoden zur behandlung von diabetes
NO20061085L (no) Kombinasjonsterapi for glykemisk kontroll
MA29397B1 (fr) Methode de traitement ou de prevention du diabete de type 2
TW200745044A (en) Pyrazole derivatives, compositions containing such compounds and methods of use
WO2007145707A3 (en) Use of non-hydroxide bases with heat for relaxing or straightening hair
BR0103209A (pt) Uso de ácido fitânico para o tratamento de diabetes
MXPA06002315A (es) Abridores de canal erg para el tratamiento de arritmias cardiacas.
WO2005053728A3 (de) Mit adipositas assoziierte proteine und deren verwendung in therapie und diagnostik
WO2024163383A3 (en) Treating spinal muscular atrophy (sma) by modulating mir34 and use of mir34 as a predictive biomarker of sma
NO20012301L (no) Ny fremgangsmåte for behandling

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application